NCT06586671View on ClinicalTrials.gov

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions
Hematological Malignancy
Interventions
DRUG

Nemtabrutinib

Oral administration

Trial Locations (1)

33143

QPS-MRA, LLC-Early Phase (Site 0002), South Miami

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06586671 - A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) | Biotech Hunter | Biotech Hunter